Shubham Dutta, Ph.D.

 ^{1 1} February 2019.  I am a Senior Research Scientist at Massbiologics Non-Human Primate Reagent Research (NHPRR) group. I lead antibody development in the neotropic NHP part of the group. My work here is to develop validated antibodies that are used in both in vitro and in vivo in preclinical NHP studies.

I completed my Ph.D. in Biomedical Sciences from University of Massachusetts Medical School in 2018. Previously, I did my MS in Biophysics and Molecular Biology and BS in Microbiology from University of Calcutta.

Experience §

Senior Research Scientist @ Massbiologics ^{2 2} Sep 2020–Present
Boston, MA 
Developing validated in vivo and in vitro monoclonal and bispecific antibodies for preclinical NHP studies.

Scientist II @ Totient Inc. ^{3 3} Sep 2018–Jan 2020
Cambridge, MA 
Executing CRISPR and antibody screens in lung adenocarcinoma.

Postdoctoral fellow @ UMass Chan Medical School ^{4 4} Apr 2018–Aug 2018
Worcester, MA 
CRISPR screen to identify novel epigenetic regulators in Ewing’s Sarcoma and executed genome-wide shRNA and RNAi screens to uncover regulators of X-chromosome inactivation

Education §

Ph.D. in Biomedical Sciences ^{5 5} 2011–2018
Worcester, MA 
University of Massachusetts Chan Medical School

M.S. in Biophysics and Molecular Biology ^{6 6} 2008–2010
Kolkata, WB, India 
University of Calcutta

B.S. in Microbiology ^{7 7} 2005–2008
Kolkata, WB, India 
University of Calcutta

Publications §

• Dutta, S. (2025). Dendritic cell-based immunotherapies for cancer. In A. K. Mishra & S. K. Malonia (Eds.), Cell-based immunotherapies for cancer (pp. 327–351). Springer Nature
• Dutta, S. (2024). Tidyplate: Transform microplate data into tibbles. CRAN.
• Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022). Emerging trends in immunotherapy for cancer. Diseases
• Banerjee, A., Malonia, S. K., & Dutta, S. (2021). Frontiers of CRISPR-Cas9 for cancer research and therapy. J. Explor. Res. Pharmacol
• Dutta, S., Mana-Capelli, S., Paramasivam, M., Dasgupta, I., Cirka, H., Billiar, K., & McCollum, D. (2018). TRIP6 inhibits hippo signaling in response to tension at adherens junctions. EMBO Rep
• Bindu, S., Pal, C., Dey, S., Goyal, M., Alam, A., Iqbal, M. S., Dutta, S., Sarkar, S., Kumar, R., Maity, P., & Bandyopadhyay, U. (2015). Translocation of heme oxygenase-1 to mitochondria is a novel cytopro- tective mechanism against non-steroidal anti-inflammatory drug-induced mitochondrial oxidative stress, apoptosis, and gastric mucosal injury. J. Biol. Chem
• Mana-Capelli, S., Paramasivam, M., Dutta, S., & McCollum, D. (2014). Angiomotins link f-actin architecture to hippo pathway signaling. Mol. Biol. Cell